Cheng et al. demonstrated that the FABP4/uncoupling protein 2 (UCP2) axis drives resistance to cetuximab in drug-tolerant persister cells and KRAS-mutated CRC models, primarily by supporting metabolic dormancy and adipocyte-induced lipid remodelling [105]. The gene discussed is UCP2; the disease is colorectal carcinoma.